CeQur® SA, a leader in simple insulin infusion for people with type 2 diabetes, announced the appointment of Robert Farra as chief executive officer, effective today.

Farra has a more than 30-year record of leading organizations in the development of novel
products, including drug delivery devices, medical devices, and sensors in the diabetes, cardiac,
and surgical fields. Prior to joining CeQur, he was with Microchips Biotech, a developer of
wirelessly-enabled drug delivery and sensing implants, where he held senior roles including
president, chief technology officer, and vice president of R&D. Farra has extensive expertise
and medtech capabilities that are essential to CeQur, including electro-mechanical and fluidicbased
medical devices, drug delivery technologies and automation equipment.

“Over the course of his career, Bob has demonstrated that he can transform technologies into
successful commercial products,” said Eric Milledge, chairman of CeQur. “He has the very
specific background we sought in a CEO to lead CeQur at this point in the company’s evolution
– deep experience developing both medical and drug-delivery technologies, and proven
leadership capabilities.”

CeQur is optimizing PAQ for high-volume, low-cost manufacturing and continuing to amass
clinical evidence that demonstrate PAQ will offer a safe, simple-to-use and cost-effective
alternative to daily insulin injections for people with type 2 diabetes.

“CeQur is driven by outstanding industry leaders who are committed to developing a novel
product that will have a real impact on the health and daily lives of the estimated 5 million
people with type 2 diabetes injecting insulin,” said Farra. “I look forward to working with the
CeQur team to advance and commercialize PAQ, for the benefit of those who need insulin and
wish to free themselves from multiple daily injections.”